At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 11,145 enrolled
Drug / intervention
cangrelor P2Y12 (platelet) inhibitor +2 moredrug
Likely dose
Clopidogrel - 300 or 600 mg (study arm)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)
In Brief
A Phase 3 clinical trial evaluating cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), and 1 other intervention for Atherosclerosis and 2 related conditions. Completed, enrolled 11,145 participants across 1 site.
Detailed Summary
The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartSep 2010
Primary CompletionDec 2012
TodayJul 2026
First PostedJul 5, 2010
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.0 years ago
Interventions
cangrelor P2Y12 (platelet) inhibitordrug
Clopidogrel - 300 or 600 mg (study arm)drug
Over encapsulated tablets.
Clopidogrel 600 mg post cangrelordrug
over-encapsulated clopidogrel (600 mg)